Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Receives Consensus Recommendation of “Buy” from Analysts

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) has been given a consensus recommendation of “Buy” by the six analysts that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued a report on the stock in the last year is $25.60.

Several research firms recently commented on ATNM. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Actinium Pharmaceuticals in a research report on Monday, June 17th. Maxim Group upped their price target on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th. Stephens started coverage on shares of Actinium Pharmaceuticals in a research report on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 price target for the company. Finally, StockNews.com upgraded shares of Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, May 5th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sanders Morris Harris LLC purchased a new position in shares of Actinium Pharmaceuticals during the 1st quarter worth about $78,000. Creative Financial Designs Inc. ADV raised its holdings in Actinium Pharmaceuticals by 19.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 3,175 shares during the period. Virtu Financial LLC raised its holdings in Actinium Pharmaceuticals by 319.2% in the first quarter. Virtu Financial LLC now owns 82,029 shares of the biotechnology company’s stock valued at $642,000 after buying an additional 62,459 shares during the period. Brandywine Global Investment Management LLC purchased a new position in Actinium Pharmaceuticals in the third quarter valued at approximately $1,033,000. Finally, Vanguard Group Inc. raised its holdings in Actinium Pharmaceuticals by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the biotechnology company’s stock valued at $11,325,000 after buying an additional 82,113 shares during the period. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Stock Down 2.4 %

Shares of ATNM opened at $7.37 on Friday. The stock has a market cap of $219.48 million, a price-to-earnings ratio of -4.31 and a beta of 0.12. Actinium Pharmaceuticals has a 1-year low of $4.00 and a 1-year high of $10.24.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings results on Friday, April 26th. The biotechnology company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.11. As a group, equities research analysts predict that Actinium Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.